A phase 1b randomized single-blind placebo-controlled delayed-start clinical trial of UB-312 in subjects with synucleinopathies

Brief description of study

A phase 1b randomized, single-blind, placebo-controlled, delayed-start clinical trial of UB-312 in subjects with synucleinopathies


Clinical Study Identifier: s22-00631
ClinicalTrials.gov Identifier: NCT05634876
Principal Investigator: Horacio Kaufmann.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.